Titlebook: Hematopoietic Growth Factors in Oncology; Gary H. Lyman,David C. Dale Book 2011 Springer Science+Business Media, LLC 2011 Biology.Molecula

Auditory-Nerve

書目名稱Hematopoietic Growth Factors in Oncology影響因子(影響力)




書目名稱Hematopoietic Growth Factors in Oncology影響因子(影響力)學(xué)科排名




書目名稱Hematopoietic Growth Factors in Oncology網(wǎng)絡(luò)公開度




書目名稱Hematopoietic Growth Factors in Oncology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Hematopoietic Growth Factors in Oncology被引頻次




書目名稱Hematopoietic Growth Factors in Oncology被引頻次學(xué)科排名




書目名稱Hematopoietic Growth Factors in Oncology年度引用




書目名稱Hematopoietic Growth Factors in Oncology年度引用學(xué)科排名




書目名稱Hematopoietic Growth Factors in Oncology讀者反饋




書目名稱Hematopoietic Growth Factors in Oncology讀者反饋學(xué)科排名

爭(zhēng)吵

Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapyreceiving regimens associated with lower risk should have CSF use guided by individual risk assessment. Critical quality appraisal indicates that the scope and purpose, stakeholder involvement, and applicability of the guidelines differ little. There is more emphasis on comprehensive literature revi

過分自信

bronchiole

Ten Years of Meta-analyses on Erythropoiesis-Stimulating Agents in Cancer Patients thrombovascular events. An increased risk of thrombovascular events was observed in all but two meta-analyses (relative risks (RRs) ranging from 1.57 to 1.69). However, potential reporting and publication bias as well as detection bias call for a cautious interpretation of these results. Survival a

ATP861

Book 2011in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of

極大痛苦

Gary H. Lyman,Nicole M. Kuderere June 1-10, 1987, at the same location. At the plenary session of this meeting it was decided that future meetings should have a principal theme. The theme for the third meeting (June 1- 10, 1989, Kupuri) was Karamata‘s Regular Variation. The principal theme for the fourth meeting (June 1-10, 1990,

Rinne-Test

注意力集中

0927-3042 ty of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of 978-1-4614-2728-5978-1-4419-7073-2Series ISSN 0927-3042 Series E-ISSN 2509-8497

易受刺激

值得尊敬

Early-Acting Hematopoietic Growth Factors: Biology and Clinical Experiencet biologically interesting molecules and at least theoretically have diverse applications in the evolving field of regenerative medicine. Among this class of regulators, the early-acting hematopoietic growth factors and their cellular targets are perhaps the best characterized and serve as a paradig